-
Nov.252024NEWS
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion ..
-
Nov.012024NEWS
HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business
HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business
-
Jul.262024NEWS
HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business
HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business
-
Jul.152024NEWS
HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer
HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer
-
May.282024NEWS
HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases
HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for..
-
May.072024NEWS
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELO..